Development of anti-androgen ARN-509 1 ARN-509: a novel anti-androgen for prostate cancer treatment

Nicola J. Clegg, John Wongvipat, Jim Joseph, Chris Tran, Samedy Ouk, Anna Dilhas, Yu Chen, Kate Grillot, Eric D. Bischoff , Ling Cai, Anna Aparicio, Steven Dorow, Vivek Arora, Gang Shao, Jing Qian, Hong Zhao, Guangbin Yang, Chunyan Cao, John Sensintaffar, Teresa Wasielewska, Mark R. Herbert, Celine Bonnefous, Beatrice Darimont, Howard I. Scher, Peter Smith-Jones, Mark Klang, Nicholas D. Smith, Elisa De Stanchina, Nian Wu, Ouathek Ouerfelli, Peter J. Rix, Richard A. Heyman, Michael E. Jung, Charles L. Sawyers Jeffrey H. Hager Human Oncology & Pathogenesis Program & Howard Hughes Medical Institute, Organic Synthesis Core Facility, Molecular Pharmacology & Chemistry, Research Pharmacy Core Facility, Antitumor Assessment Core Facility, Analytical Pharmacology Core Facility, Genitourinary Oncology Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY 10065; Department of Chemistry and Biochemistry, University of California, Los Angeles, CA 90095; Aragon Pharmaceuticals, Inc., San Diego, CA 92130.